SNSS - Anticancer Activity Demonstrated in Both Hematologic and Solid Malignancies
We are currently evaluating vosaroxin in clinical trials of acute myeloid leukemia (AML) and platinum-resistant ovarian cancer. We have 2 ongoing trials in AML: a Phase 1b/2 combination clinical trial of vosaroxin with cytarabine in patients with relapsed and/or refractory acute myeloid leukemia, as well as a Phase 2 single agent trial for elderly patients with newly diagnosed and previously untreated AML, known as REVEAL-1 (Response Evaluation of Vosaroxin in AML).
Vosaroxin has demonstrated objective tumor responses in a variety of tumor types and has been generally well tolerated. Clinical responses with single agent vosaroxin have been seen in these indications, as well as in non-small cell and small cell lung cancers. In addition, complete remissions have been observed in AML patients treated with vosaroxin in combination with cytarabine.
Vosaroxin is a replication-dependent DNA-damaging agent that induces G2 arrest and apoptosis (cell death). As a result, cancer cells, which are typically proliferative and resistant to pathways that eliminate damaged or aberrant cells, are no longer able to divide and the cells die. Based on our translational research and our understanding of Vosaroxin's mechanism of action, vosaroxin has the potential to combine with other anticancer agents for the treatment of both advanced and earlier stage disease. Click here for more information on vosaroxin's mechanism of action.
News 
Market Data 
Discover 
